EMBO Mol Med (2019) 11:e9466

Introduction {#emmm201809466-sec-0001}
============

Mitochondria are the primary site of cellular energy production and can also have a broad range of other vital functions for the cells. Dysfunction of mitochondria is observed in common age‐related disorders, including neurodegenerative diseases, metabolic syndrome, cardiomyopathies, and sarcopenia (Nunnari & Suomalainen, [2012](#emmm201809466-bib-0052){ref-type="ref"}). Mitochondrial dysfunction is likewise the primary characteristic of monogenic disorders that affect one of the genes that encode the estimated 1,000 proteins identified in mitochondria (Pagliarini *et al*, [2008](#emmm201809466-bib-0054){ref-type="ref"}). Among these, mutations in genes encoding essential proteins for the oxidative phosphorylation (OXPHOS) system account for the most common group of inborn errors of metabolism. The therapeutic options for these disorders are mostly limited to palliative care and remain woefully inadequate (DiMauro *et al*, [2013](#emmm201809466-bib-0015){ref-type="ref"}; Wang *et al*, [2016](#emmm201809466-bib-0069){ref-type="ref"}).

Primary deficiency of coenzyme Q10 (CoQ~10~), due to CoQ~10~ biosynthetic defects, is a mitochondrial syndrome that affects the OXPHOS system, and it has heterogeneous clinical presentations and variable response to therapy with exogenous CoQ~10~ (DiMauro *et al*, [2007](#emmm201809466-bib-0014){ref-type="ref"}; Emmanuele *et al*, [2012](#emmm201809466-bib-0018){ref-type="ref"}). To understand the disease mechanisms, we previously generated and characterized the first mouse model of mitochondrial encephalopathy due to CoQ deficiency. The mouse model presents two point mutations, leading to a premature stop codon in *Coq9* (*Coq9* ^*R239X*^; Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}). These mutations are homologues to the mutations identified in a patient (*COQ9* ^*R244X*^; Duncan *et al*, [2009](#emmm201809466-bib-0017){ref-type="ref"}). The resulting dysfunctional COQ9 protein causes a profound reduction in the levels of COQ7 protein and disruption of the multiprotein complex for CoQ biosynthesis (Complex Q), resulting in a severe CoQ deficiency with accumulation of demethoxyubiquinone (DMQ = 2‐polyprenyl‐6‐methoxy‐3‐methyl‐1,4‐benzoquinone), brain mitochondrial dysfunction, oxidative damage, disruption of sulfide metabolism, reactive astrogliosis, spongiform degeneration, hypotension, and premature death (Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}; Luna‐Sanchez *et al*, [2017](#emmm201809466-bib-0048){ref-type="ref"}). These pathological features are similar to those described in patients with mutations in *COQ7* and *COQ9*, who presented a severe early‐onset multisystemic disease dominated by encephalopathy, the phenotype associated with CoQ deficiency with the most limited response to oral CoQ~10~ supplementation (Lopez *et al*, [2006](#emmm201809466-bib-0045){ref-type="ref"}; Duncan *et al*, [2009](#emmm201809466-bib-0017){ref-type="ref"}; Emmanuele *et al*, [2012](#emmm201809466-bib-0018){ref-type="ref"}; Danhauser *et al*, [2016](#emmm201809466-bib-0009){ref-type="ref"}; Smith *et al*, [2018](#emmm201809466-bib-0062){ref-type="ref"}).

Consistent with the poor therapeutic effects of CoQ supplementations in patients, oral supplementation with ubiquinone‐10, the oxidized form of CoQ~10~, was ineffective in the *Coq9* ^*R239X*^ mouse model due to its poor absorption and bioavailability, which is more accused in the CNS because of the presence of the blood brain barrier (Bentinger *et al*, [2003](#emmm201809466-bib-0003){ref-type="ref"}; Bhagavan & Chopra, [2007](#emmm201809466-bib-0004){ref-type="ref"}; Lopez *et al*, [2010](#emmm201809466-bib-0046){ref-type="ref"}; Garcia‐Corzo *et al*, [2014](#emmm201809466-bib-0024){ref-type="ref"}). The supplementation with ubiquinol‐10, the reduced form of ubiquinone‐10, provided better therapeutic outcomes because it induced slight improvements in mitochondrial bioenergetics in the brain and reduction of the oxidative stress and astrogliosis (Garcia‐Corzo *et al*, [2014](#emmm201809466-bib-0024){ref-type="ref"}).

An alternative strategy to the exogenous CoQ~10~ supplementation is to increase the endogenous CoQ biosynthesis. The biosynthesis of CoQ~10~ occurs in a complex biosynthetic pathway in which the 4‐hydroxybenzoic acid (4‐HB) is the initial substrate. This precursor of the benzoquinone ring of CoQ is first prenylated, and then, a total of seven reactions (one decarboxylation, three hydroxylation, and three methylation) produce the fully substituted benzoquinone ring of CoQ (Fig [EV1](#emmm201809466-fig-0001ev){ref-type="fig"}; Kawamukai, [2016](#emmm201809466-bib-0036){ref-type="ref"}). One of the hydroxylation steps is catalyzed by COQ7, a hydroxylase that needs another protein, COQ9, for its stability and normal function (Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}; Lohman *et al*, [2014](#emmm201809466-bib-0044){ref-type="ref"}). The hydroxyl group incorporated by COQ7 into the benzoquinone ring is already present in the molecule β‐resorcylic acid (β‐RA), also named 2,4‐hydroxybenzoic acid (2,4‐diHB). Therefore, β‐RA is a 4‐HB analog that can be theoretically used in the CoQ biosynthesis pathway in order to bypass a defect from the hydroxylation step catalyzed by COQ7 (Fig [EV1](#emmm201809466-fig-0001ev){ref-type="fig"}). This strategy was partially successful *in vitro* in *COQ7* null yeasts, as well as in mouse and human fibroblasts with mutations in *COQ7* or *COQ9* (Xie *et al*, [2012](#emmm201809466-bib-0071){ref-type="ref"}; Freyer *et al*, [2015](#emmm201809466-bib-0022){ref-type="ref"}; Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}). Additionally, β‐RA is a structural analogue of salicylic acid (2‐hydroxybenzoic acid), an anti‐inflammatory molecule that may be potentially valuable to reduce the neuroinflammation (Lan *et al*, [2011](#emmm201809466-bib-0038){ref-type="ref"}; Gomez‐Guzman *et al*, [2014](#emmm201809466-bib-0026){ref-type="ref"}), a factor that has been recently postulated as an essential pathomechanism and a therapeutic target in mitochondrial encephalopathies (Ignatenko *et al*, [2018](#emmm201809466-bib-0034){ref-type="ref"}), leukoencephalopathy, and neurodegenerative diseases (Eto *et al*, [2002](#emmm201809466-bib-0019){ref-type="ref"}; Liddelow & Barres, [2015](#emmm201809466-bib-0041){ref-type="ref"}, [2017](#emmm201809466-bib-0042){ref-type="ref"}). Also salicylic derivate, known as salicylates, may act as mTOR inhibitors (Cameron *et al*, [2016](#emmm201809466-bib-0007){ref-type="ref"}), and this action may be therapeutic in mitochondrial diseases (Johnson *et al*, [2013](#emmm201809466-bib-0035){ref-type="ref"}).

![CoQ biosynthetic pathway, including the bypass hypothesis for defects in COQ9 or COQ7\
4‐HB = 4‐hydroxybenzoic acid; DMQ = demethoxyubiquinone or 2‐polyprenyl‐6‐methoxy‐3‐methyl‐1,4‐benzoquinone; DMeQ = 2‐polyprenyl‐5‐hydroxy‐6‐methoxy‐3‐methyl‐1,4‐benzoquinone; β‐RA = β‐resorcylic acid. The purple circle indicates the OH group present in the β‐RA and absent in the 4‐HB. The hydroxylation of DMQ is normally catalyzed by COQ7, which needs COQ9 for its stability and activity. This step is compromised in patients with defects in COQ7 or COQ9. The pathway is exampled with the production of CoQ~10~.](EMMM-11-e9466-g003){#emmm201809466-fig-0001ev}

Based on the properties of β‐RA, we have evaluated its therapeutic potential in a mouse model of mitochondrial encephalopathy due to CoQ deficiency. Our data show novel therapeutic mechanisms and represent one of the few cases of successful therapies for mitochondrial encephalopathies that could easily be implemented into the clinic.

Results {#emmm201809466-sec-0002}
=======

The treatment with β‐RA rescues the phenotype of Coq9^R239X^ mice {#emmm201809466-sec-0003}
-----------------------------------------------------------------

We previously demonstrated that *Coq9* ^*R239X*^ mice have reduced size and body weight, and die between 3 and 7 months of age (Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}). Moreover, we proved that ubiquinol‐10 treatment induces biochemical and histopathological improvements in the brain of *Coq9* ^*R239X*^ mice (Garcia‐Corzo *et al*, [2014](#emmm201809466-bib-0024){ref-type="ref"}). These improvements led to a significant increase in the survival of *Coq9* ^*R239X*^ mice treated with ubiquinol‐10, compared to the *Coq9* ^*R239X*^ mice. While the *Coq9* ^*R239X*^ mice reached a maximum age of 7 months, with a median survival of 5 months of age, the *Coq9* ^*R239X*^ mice treated with ubiquinol‐10 reached a maximum age of 17 months, with a median survival of 13 months of age (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}A). Interestingly, the therapeutic effect of oral β‐RA supplementation resulted in an even greater increase in the survival of *Coq9* ^*R239X*^ mice, reaching a maximum lifespan of 25 months of age, with a median survival of 22 months of age (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}A). Therefore, the extension in the lifespan achieved by β‐RA in *Coq9* ^*R239X*^ mice reached values close to the lifespan in wild‐type mice (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}A). Analysisusing the log‐rank (Mantel‐Cox) and the Gehan--Breslow--Wilcoxon tests shows significant differences (*P* \< 0.0001 and *P* = 0.0017, respectively) between *Coq9* ^+/+^ mice, *Coq9* ^*R239X*^ mice, *Coq9* ^*R239X*^ mice treated with β‐RA, and *Coq9* ^*R239X*^ mice treated with ubiquinol‐10 (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}A). Moreover, if the β‐RA treatment started at 3 months of age (symptomatic period) instead of 1 month of age (asymptomatic period), 100% of the treated mice remained alive at 14 months of age (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}B).

![Survival and phenotypic characterization of *Coq9* ^*R239X*^ mice after β‐RA treatment\
ASurvival curve of the *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment and *Coq9* ^*R239X*^ after ubiquinol‐10 treatment. The treatments started at 1 month of age \[Log‐rank (Mantel‐Cox) test or Gehan--Breslow--Wilcoxon test; *Coq9* ^+/+^, *n* = 9; *Coq9* ^*R239X*^, *Coq9* ^*R239X*^ after β‐RA treatment, and *Coq9* ^*R239X*^ after ubiquinol‐10 treatment, *n* = 15 for each group\].BSurvival curve of the *Coq9* ^*R239X*^ mice and *Coq9* ^*R239X*^ mice after β‐RA treatment started at 3 months of age (*Coq9* ^*R239X*^, *n* = 15; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 10).C, DBody weight of males (C) and females (D) *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment \[(C): *Coq9* ^+/+^, *n* = from 31 to 4; *Coq9* ^*R239X*^, *n* = from 13 to 13; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = from 31 to 7. (D): *Coq9* ^+/+^, *n* = from 22 to 3; *Coq9* ^*R239X*^, *n* = from 13 to 12; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = from 24 to 3\].E, FRotarod test of male (E) and female (F) *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment \[(E): *Coq9* ^+/+^, *n* = from 11 to 8; *Coq9* ^*R239X*^, *n* = from 10 to 10; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = from 11 to 9. (F): *Coq9* ^+/+^, *n* = from 5 to 5; *Coq9* ^*R239X*^, *n* = from 4 to 4; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = from 11 to 6\].GBlood pressure of *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment. Data from male and female mice are represented together (*Coq9* ^+/+^, *n* = 6; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 7). The whiskers down and up of the boxes indicate the minimum and maximum value, respectively. Horizontal lines inside the boxes mark the median.HComparative image of a *Coq9* ^*R239X*^ mouse and a *Coq9* ^*R239X*^ mouse after β‐RA treatment at 4 months of age.Data information: Data are expressed as mean ± SD. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; *Coq9* ^*R239X*^ or *Coq9* ^*R239X*^ after β‐RA treatment versus *Coq9* ^+/+^. ^+^ *P* \< 0.05; ^+^ ^+^ *P* \< 0.01; *Coq9* ^*R239X*^ versus *Coq9* ^*R239X*^ after β‐RA treatment (one‐way ANOVA with a Tukey\'s *post hoc* test or *t*‐test; see [Appendix Table S2](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values).](EMMM-11-e9466-g002){#emmm201809466-fig-0001}

The striking increase in survival was in parallel of/accompanied by a phenotypic improvement*. Coq9* ^*R239X*^ mice treated with β‐RA showed a slight increase in the body weight, although the values did not reach the wild‐type levels (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}C and D). The motor coordination tested by rotarod assay showed a decrease in the latency to fall in *Coq9* ^*R239*X^ mice compared to *Coq9* ^+/+^ mice. The treatment with β‐RA significantly attenuated the motor phenotype in *Coq9* ^*R239X*^ mice, both in males and females (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}E and F). The treatment also normalized the blood pressure (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}G), while the blood cells and hemoglobin levels did not change in the experimental groups ([Appendix Fig S1](#emmm201809466-sup-0008){ref-type="supplementary-material"}). The general health improvement of *Coq9* ^*R239X*^ mice treated with β‐RA was remarkable, clearly showing a healthier demeanor, compared to the untreated *Coq9* ^*R239X*^ mice (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}H and [Movie EV1](#emmm201809466-sup-0005){ref-type="supplementary-material"}).

The treatment with β‐RA induces a reduction in the histopathological signs of the encephalopathy {#emmm201809466-sec-0004}
------------------------------------------------------------------------------------------------

Because of the striking effect of the treatment on the survival and health status of the *Coq9* ^*R239X*^ mice, we performed a histopathological evaluation of the brain, the main symptomatic tissue. The spongiform degeneration and reactive astrogliosis characteristic in the diencephalon (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}B~1~, E~1~, H~1~, and K~1~) and the pons ([Appendix Fig S2](#emmm201809466-sup-0008){ref-type="supplementary-material"}) of the *Coq9* ^*R239X*^ mice (Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}), compared to *Coq9* ^+/+^ mice (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}A~1~, D~1~, G~1~, and J~1~; [Appendix Fig S2](#emmm201809466-sup-0008){ref-type="supplementary-material"}), almost disappeared after the β‐RA treatment (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}C~1~, F~1~, I~1~, and L~1~; [Appendix Fig S2](#emmm201809466-sup-0008){ref-type="supplementary-material"}). The microglia distribution did not show any difference between the three experimental groups (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}M~1~--R~1~; [Appendix Fig S2](#emmm201809466-sup-0008){ref-type="supplementary-material"}). Moreover, the increased protein oxidation observed in the diencephalon of *Coq9* ^*R239X*^ mice (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}T~1~), compared to *Coq9* ^+/+^ mice (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}S~1~), was attenuated in *Coq9* ^*R239X*^ mice treated with β‐RA (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}U~1~).

![Pathological features in the brain of *Coq9* ^*R239X*^ mice after β‐RA treatment\
A--U(A~1~--F~1~) H&E stain in the diencephalon of *Coq9* ^+/+^ mice (A~1~ and D~1~)*, Coq9* ^*R239X*^ mice (B~1~ and E~1~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (C~1~ and F~1~). (G~1~--L~1~) Anti‐GFAP stain in the diencephalon of *Coq9* ^+/+^ mice (G~1~ and J~1~)*, Coq9* ^*R239X*^ mice (H~1~ and K~1~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (I~1~ and L~1~). (M~1~--R~1~) Anti‐Iba1 stain in the diencephalon of *Coq9* ^+/+^ mice (M~1~ and P~1~)*, Coq9* ^*R239X*^ mice (N~1~ and Q~1~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (O~1~ and R~1~). (S~1~--U~1~) Protein oxidation in the diencephalon of *Coq9* ^+/+^ mice (S~1~)*, Coq9* ^*R239X*^ mice (T~1~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (U~1~). (A~2~--C~2~) Magnetic Resonance Images of the diencephalon of *Coq9* ^+/+^ mice (A~2~)*, Coq9* ^*R239X*^ mice (B~2~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (C~2~). (D~2~--F~2~) Magnetic Resonance Images of the pons of *Coq9* ^+/+^ mice (D~2~)*, Coq9* ^*R239X*^ mice (E~2~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (F~2~). (G~2~--I~2~) Lactate peak in the brain of *Coq9* ^+/+^ mice (G~2~)*, Coq9* ^*R239X*^ mice (H~2~), and *Coq9* ^*R239X*^ mice after β‐RA treatment (I~2~). Scale bars: 1 mm (A~1~--C~1~); 100 μm (D~1~--F~1~); 200 μm (G~1~--I~1~); 100 μm (J~1~--L~1~); 200 μm (M~1~--O~1~); 100 μm (P~1~--R~1~); 100 μm (S~1~--U~1~). The yellow arrows indicated the areas of increased T2 signal, which is characteristic of lesions in specific brain areas.](EMMM-11-e9466-g004){#emmm201809466-fig-0002}

The improvements in the histopathological features were further corroborated by magnetic resonance imaging (MRI). Brain injuries were observed in the diencephalon and the pons of *Coq9* ^*R239X*^ mice (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}B~2~--E~2~; [Appendix Fig S2](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In *Coq9* ^+/+^ mice and *Coq9* ^*R239X*^ mice treated with β‐RA, however, we did not detect any sign of brain injury (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}A~2~, D~2~, C~2~ and F~2~; [Appendix Fig S2](#emmm201809466-sup-0008){ref-type="supplementary-material"}), suggesting that the treatment normalized the cerebral structure.

Nevertheless, the cerebral lactate levels, that are increased in *Coq9* ^*R239X*^ mice (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}H~2~) compared to *Coq9* ^+/+^ mice (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}G~2~), remained increased in *Coq9* ^*R239X*^ mice after the treatment (Fig [2](#emmm201809466-fig-0002){ref-type="fig"}I~2~).

In the skeletal muscle, the cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) stainings showed an increase in type II fibers in *Coq9* ^*R239X*^ mice. After the treatment with β‐RA, the proportion of type I and type II fibers was normalized (Fig [EV2](#emmm201809466-fig-0002ev){ref-type="fig"}).

![COX and SDH staining in *gastrocnemius*\
A--CCOX stains in *gastrocnemius* of *Coq9* ^+/+^ mice (A), *Coq9* ^*R239X*^ mice (B), and *Coq9* ^*R239X*^ mice after β‐RA treatment (C).D--FSDH stain in *gastrocnemius* of *Coq9* ^+/+^ mice (D), *Coq9* ^*R239X*^ mice (E), and *Coq9* ^*R239X*^ mice after β‐RA treatment (F).Data information: "I" indicated fiber types I and "II" indicates fiber types II.](EMMM-11-e9466-g005){#emmm201809466-fig-0002ev}

Transcriptomics profile reveals a reduction in the neuroinflammatory genes {#emmm201809466-sec-0005}
--------------------------------------------------------------------------

Next, we carried out an RNA‐Seq experiment on brainstems from the three experimental mice groups, e.g., *Coq9* ^+/+^, *Coq9* ^*R239X*^, and *Coq9* ^*R239X*^ treated with β‐RA. The over 9 × 10^9^ bases of the 101‐bases sequencing reads aligned to 27,291 loci of the reference mouse genome. As Fig [3](#emmm201809466-fig-0003){ref-type="fig"}A shows, 298 genes were over‐expressed in the *Coq9* ^*R239X*^ mice compared to the *Coq9* ^+/+^ mice, while 161 were under‐expressed. On the other hand, 187 genes were over‐expressed in the *Coq9* ^*R239X*^ mice compared to the *Coq9* ^*R239X*^ mice treated with β‐RA, while 160 were under‐expressed (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}A). When comparing the pathways to which these differentially expressed genes belong, we observed a noticeably higher presence of genes belonging to inflammation signaling pathways in the *Coq9* ^*R239X*^ mice compared to the β‐RA treated *Coq9* ^*R239X*^ or *Coq9* ^+/+^ mice (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}B).

![Effect of the β‐RA treatment on genes expression profiles and neuroinflammatory‐related features\
AGlobal differences in the levels of gene expression between experimental groups.BOnly pathways with more than one gene significantly altered in *Coq9* ^*R239X*^ compared to *Coq9* ^+/+^ mice are considered for this figure. The *y*‐axis represents the percentage of genes corresponding to a pathway in the sample of genes whose expression level is significantly altered in a comparison between mice samples.CHeatmap showing the comparative landscape of the expression level per sample of the 27 genes whose expression was altered by the mutation and normalized by the β‐RA treatment. The column numbers correspond to the different samples and the row names are gene codes composed of the ENSEMBL gene ID and the gene symbol (between parentheses). The green means comparatively higher, red means comparatively lower, and black means no difference in expression level (*n* = 5 for each group).DiNOS expression levels in RAW cells after stimulation with LPS (*n* = 3 for each group).ECytokine levels in the culture supernatant of RAW cells after stimulation with LPS (*n* = 3 for each group).FCytokine levels in the brainstem of *Coq9* ^+/+^ mice, *Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice treated with β‐RA (*n* = 7 for each group).G, HMortality rate (G) and (H) percentage of malformations in zebrafish embryos treated with MPT and the effect of β‐RA treatment.ISurvival curve of *Ndufs4* knockout mice and *Ndufs4* knockout mice treated with β‐RA \[Log‐rank (Mantel‐Cox) test; *n* = 5 for each group; see [Appendix Table S3](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values\].Data information: Data in panels (D--F) are expressed as mean ± SD. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; LPS or LPS + β‐RA versus control. ^+^ *P* \< 0.05; LPS or LPS + β‐RA versus control (one‐way ANOVA with a Tukey\'s *post hoc* test; see [Appendix Table S3](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values).](EMMM-11-e9466-g006){#emmm201809466-fig-0003}

Of the 459 genes whose expression is significantly altered in *Coq9* ^*R239X*^ mice compared to *Coq9* ^+/+^, 27 were significantly altered in *Coq9* ^*R239X*^ mice treated with β‐RA compared to *Coq9* ^*R239X*^ mice. Interestingly, among these 27 genes, the ones that were over‐expressed in *Coq9* ^*R239X*^ mice, compared to the *Coq9* ^+/+^ mice, became under‐expressed in *Coq9* ^*R239X*^ mice treated with β‐RA, compared to *Coq9* ^*R239X*^ mice, and *vice versa* (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}C). Thus, the levels of these 27 genes were normalized. Most of these genes showed higher expression in *Coq9* ^*R239X*^ mice compared to *Coq9* ^+/+^ mice, and they mainly have inflammation and immune‐related functions. For example, the inflammatory genes *Bgn* (biglycan), *Ccl6* (chemokine C‐C motif ligand 6), *Cst7* (cystatin F), *Ifi27l2a* (interferon, alpha‐inducible protein 27 like 2A), Ifitm3 (interferon‐induced transmembrane protein 3), *Itgax* (integrin alpha X), and *Vav1* are up‐regulated in *Coq9* ^*R239X*^ mice and normalized after the treatment.

β‐RA does not directly act as anti‐inflammatory agent {#emmm201809466-sec-0006}
-----------------------------------------------------

Because the transcriptomics profile uncovers a possible involvement of neuroinflammation in the therapeutic effect of β‐RA, and since this molecule is an analogue of the anti‐inflammatory salicylic acid, we tested whether β‐RA may have a direct anti‐inflammatory action. First, we incubated RAW cells with 1 μg/ml LPS, which induces a NF‐κB‐mediated inflammatory response, as it is shown by the induction of iNOS (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}D) and the release of IL‐1β, IL‐2, and TNF‐α (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}E). The pre‐incubation with β‐RA, however, did not modify the cellular iNOS expression (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}D) or the cytokine levels in the cells supernatants (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}E). Second, we quantified the cytokine levels in the brainstem of the three animals' experimental groups. The levels of IL‐1β, IL‐2, IFN‐γ, Gro‐α, and TNF‐α did not experience major changes (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}F). Third, we tested whether β‐RA may increase the survival in two models of neuroinflammation and early death due to mitochondrial Complex I deficiency, i.e., the zebrafish embryos treated with MPTP, which mimics Parkinson disease (Diaz‐Casado *et al*, [2018](#emmm201809466-bib-0013){ref-type="ref"}); and the *Ndufs4* knockout mouse model, which mimics Leigh syndrome (Quintana *et al*, [2010](#emmm201809466-bib-0056){ref-type="ref"}). In both cases, the treatment with β‐RA did not induce any change in the animal survival (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}G and I) or the presence of malformations (Fig [3](#emmm201809466-fig-0003){ref-type="fig"}H). Because the inhibition of mTORC1 may mediate the anti‐inflammatory actions of salicylates (Cameron *et al*, [2016](#emmm201809466-bib-0007){ref-type="ref"}), we also quantified the S6RP/S6R ratio as a marker of mTORC1 activity. Consistently with the other data, the β‐RA did not modify the S6RP/S6R ratio in the brain ([Appendix Fig S3A](#emmm201809466-sup-0008){ref-type="supplementary-material"}) and the kidneys ([Appendix Fig S3B](#emmm201809466-sup-0008){ref-type="supplementary-material"}) of *Coq9* ^*R239X*^ mice treated with β‐RA, suggesting that this molecule does not inhibit mTORC1 *in vivo*. Overall, these results do not support a direct role of β‐RA in the repression of the typical neuroinflammatory pathways.

β‐RA improves mitochondrial bioenergetics in peripheral tissues of *Coq9* ^*R239X*^ mice {#emmm201809466-sec-0007}
----------------------------------------------------------------------------------------

The persistent lactate peak observed in the brain spectroscopy after the β‐RA treatment suggests that the treatment does not have any effect on mitochondrial bioenergetics in the brain. To confirm this premise, we evaluated the mitochondrial function in the brain, but also in the kidneys, muscle, and heart (tissues clinically important in CoQ deficiency syndrome) of *Coq9* ^+/+^ mice, *Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice treated with β‐RA.

In the brain of the mutant mice, the activities of the CoQ‐dependent mitochondrial Complexes I+III (CI+III) and CII+III, the levels of sulfide:quinone oxidoreductase (SQOR), the assembly of C‐III into the supercomplexes (SC), and the mitochondrial oxygen consumption rate (OCR) were significantly decreased (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}A--E) compared to the values of wild‐type animals. The β‐RA treatment did not induce any change in those parameters in the brain of *Coq9* ^*R239X*^ mice (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}A--E). In the kidneys of the mutant mice, the activity of the CI+III, the levels of SQOR, and the OCR were significantly decreased (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}F--J), compared to the values of wild‐type animals. These changes were not due to a potential capability of β‐RA to act as an electron carrier in the mitochondrial respiratory chain because the CI+III activity did not change after adding 50 μM β‐RA into the reaction mix ([Appendix Fig S4](#emmm201809466-sup-0008){ref-type="supplementary-material"}). The β‐RA treatment partially normalized the CI+III activity and induced a significant increase of SQOR levels and the OCR (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}F--J). On the contrary, assembly of C‐I into the supercomplexes did not change in any experimental group ([Appendix Fig S5](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In the skeletal muscle of the mutant mice, the activity of the CI+III was significantly decreased, while the CII+III activity did not change (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}K and L), compared to the values of wild‐type animals. The β‐RA treatment normalized the CI+III activity (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}K). In the heart of *Coq9* ^*R239X*^ mice, the activities of the CI+III and CII+III, as well as the levels of SQOR, were significantly decreased (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}M--O), compared to the values of wild‐type animals. Again, the β‐RA treatment partially normalized the CI+III, CII+III activities, and the levels of SQOR, although partially in this case (Fig [4](#emmm201809466-fig-0004){ref-type="fig"}M--O). Therefore, these results illustrate tissue‐specific responses to β‐RA treatment in the mitochondrial bioenergetics.

![Tissue‐specific differences in mitochondrial function after β‐RA treatment in *Coq9* ^*R239X*^ mice\
A--O(A, F, K, M) CoQ‐dependent Complex I+III activities in brain (A) and kidneys (F), skeletal muscle (K), and heart (M). (A): *Coq9* ^+/+^, *n* = 5; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 7. (F): *Coq9* ^+/+^, *n* = 4; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 4. (K): *Coq9* ^+/+^, *n* = 3; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 3. (M): *Coq9* ^+/+^, *n* = 5; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 6). (B, G, L, N) CoQ‐dependent Complex II+III activities in brain (B) and kidneys (G), skeletal muscle (L) and heart (N). (B): *Coq9* ^+/+^, *n* = 5; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 7. (G): *Coq9* ^+/+^, *n* = 5; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 6. (L): *Coq9* ^+/+^, *n* = 5; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 7. (N): *Coq9* ^+/+^, *n* = 6; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 6. (C, H, O) Representative Western blot and quantitation of Western blot bands of SQOR in mitochondrial fractions of brain (C) and homogenates extracts from kidneys (H) and heart (O). (C): *Coq9* ^+/+^, *n* = 6; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 6. (H): *Coq9* ^+/+^, *n* = 4; *Coq9* ^*R239X*^, *n* = 3; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 3. (O): *Coq9* ^+/+^, *n* = 4; *Coq9* ^*R239X*^, *n* = 3; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 4. (D, I) Blue‐native gel electrophoresis (BNGE) followed by C‐III immunoblotting analysis of mitochondrial supercomplexes in brain (D) and kidneys (I). (D): *Coq9* ^+/+^, *n* = 9; *Coq9* ^*R239X*^, *n* = 10; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 11. (I): *Coq9* ^+/+^, *n* = 5; *Coq9* ^*R239X*^, *n* = 6; *Coq9* ^*R239X*^ after β‐RA treatment, *n* = 7. (E, J) Mitochondrial oxygen consumption rate (represented as State 3o, in the presence of ADP and substrates) in brain (E) and kidneys (J). The data represent three technical replicates and the figures are representative of three biological replicates. *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment were included in all graphs. Data are expressed as mean ± SD. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; *Coq9* ^*R239X*^ or *Coq9* ^*R239X*^ after β‐RA treatment versus *Coq9* ^+/+^. ^+^ *P* \< 0.05; *Coq9* ^*R239X*^ versus and *Coq9* ^*R239X*^ after β‐RA treatment (one‐way ANOVA with a Tukey\'s *post hoc* test; see [Appendix Table S4](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values).\
Source data are available online for this figure.](EMMM-11-e9466-g007){#emmm201809466-fig-0004}

β‐RA reduces DMQ~9~ in peripheral tissues of *Coq9* ^*R239X*^ mice {#emmm201809466-sec-0008}
------------------------------------------------------------------

*Coq9* ^*R239X*^ mice present widespread deficiency of CoQ~9~ (major CoQ form in rodents) and CoQ~10~ (minor CoQ form in rodents). Because COQ9 protein is needed for the COQ7 hydroxylation reaction, *Coq9* ^*R239X*^ mice also show accumulation of demethoxyubiquinone‐9 (DMQ~9~), the substrate of COQ7 (Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}). To test whether the general health improvement after β‐RA treatment was due to the effects of this compound on CoQ biosynthesis, and to check whether the tissue‐specific differences in mitochondrial bioenergetics were due to variances in the CoQ metabolism, we measured the levels of CoQ~9~, CoQ~10~ and DMQ~9~ in the most relevant tissues. As previously reported, the levels of CoQ~9~ (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}A, E, I, M and Q) and CoQ~10~ (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}B, F, J, N and R) were severely decreased in the brain (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}A and B), kidneys (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}E and F), liver (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}I and J), skeletal muscle (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}M and N), and heart (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}Q and R) of *Coq9* ^*R239X*^ mice. At the same time, the levels of DMQ~9~ were significantly increased in the same tissues (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}C, G, K, O and S) and, therefore, the DMQ~9~/CoQ~9~ ratios were significantly increased (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}D, H, L, P, and T) in *Coq9* ^*R239X*^ mice. After the treatment with β‐RA, the levels of CoQ~9~ slightly increased only in the kidneys (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}E), but not in the other tissues (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}A, I, M, and Q) of the mutant mice. CoQ~10~ also showed a trend toward increased levels in the kidneys of *Coq9* ^*R239X*^ mice after β‐RA treatment (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}F), although in the other tissues the levels of CoQ~10~ did not change after β‐RA treatment (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}B, J, N and R). Importantly, the levels of DMQ~9~ and, consequently, the DMQ~9~/CoQ~9~ ratios were significantly decreased in the kidneys (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}G and H), liver (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}K and L), skeletal muscle (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}O and P), and heart (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}S and T) of *Coq9* ^*R239X*^ mice treated with β‐RA, suggesting that β‐RA exerts an influence in the CoQ biosynthetic pathway. In the brain, however, the β‐RA treatment did not induce changes in the levels of DMQ~9~ or DMQ~9~/CoQ~9~ ratio (Fig [5](#emmm201809466-fig-0005){ref-type="fig"}C and D). Taken together, these results suggest that the improvement of mitochondrial bioenergetics occurs only in the tissues with decreased DMQ~9~/CoQ~9~ ratio after the treatment.

![Tissue‐specific differences in the levels of CoQ~9~, CoQ~10,~ and DMQ ~9~, and in the DMQ ~9~/CoQ~9~ ratio after β‐RA treatment in *Coq9* ^*R239X*^ mice\
A--TLevels of CoQ~9~ (A, E, I, M, Q), CoQ~10~ (B, F, J, N, R), and DMQ~9~ (C, G, K, O, S), as well as and DMQ~9~/CoQ~9~ ratio (D, H, L, P, T) in brain (A--D), kidney (E--H), liver (I--L), skeletal muscle (M--P), and heart (Q--T) of *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment. Data are expressed as mean ± SD. \*\**P* \< 0.01; \*\*\**P* \< 0.001; *Coq9* ^*R239X*^ or *Coq9* ^*R239X*^ after β‐RA treatment versus *Coq9* ^+/+^. ^+^ *P* \< 0.05; ^++^ *P* \< 0.01; *Coq9* ^*R239X*^ versus *Coq9* ^*R239X*^ after β‐RA treatment (one‐way ANOVA with a Tukey\'s *post hoc* test or *t*‐test; *n* = 6 for each group; see [Appendix Table S5](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values). Note that DMQ9 was undetectable in tissues from *Coq9* ^+/+^ mice as well as in muscle of *Coq9* ^*R239X*^ mice treated with β‐RA.](EMMM-11-e9466-g008){#emmm201809466-fig-0005}

To check whether the levels of CoQ~9~ and DMQ~9~ can be further modified during the time of the treatment or with a higher dose of β‐RA, we also quantified the levels of both quinones in tissues of mice after 9 months of treatment or with the double dose of β‐RA. The results showed that the levels of DMQ~9~ levels and the DMQ~9~/CoQ~9~ ratio were decreased in these two other experimental variants ([Table EV1](#emmm201809466-sup-0003){ref-type="supplementary-material"} and [Appendix Figs S6 and S7](#emmm201809466-sup-0008){ref-type="supplementary-material"}). However, no major differences were found in the results obtained under three experimental situations.

Because the tissue‐specific differences observed in DMQ~9~/CoQ~9~ ratio after β‐RA treatment could be due to the bioavailability of this compound in the tissues after oral supplementation, we quantified the levels of β‐RA in *Coq9* ^*R239X*^ mice after oral supplementation and compared the data to those obtained after acute intraperitoneal (i.p.) administration. The compound was detected in all the examined tissues, including the brain, by both oral and i.p. administration ([Table EV2](#emmm201809466-sup-0004){ref-type="supplementary-material"} and [Appendix Fig S8](#emmm201809466-sup-0008){ref-type="supplementary-material"}). The highest values of β‐RA were found in plasma and kidneys, while the results in brain and liver were similar ([Table EV2](#emmm201809466-sup-0004){ref-type="supplementary-material"} and [Appendix Fig S8](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In the non‐treated animals, β‐RA was not detected, except in the kidney of one animal ([Table EV2](#emmm201809466-sup-0004){ref-type="supplementary-material"} and [Appendix Fig S8](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In order to see whether the effect observed after the treatment was due to β‐RA and not to any other metabolite derived from it, we developed an UPLC‐MS screening experiment. The other hydroxybenzoic acid detected in the samples was the 4‐HB, but no statistic differences were found between the experimental groups ([Appendix Table S1](#emmm201809466-sup-0008){ref-type="supplementary-material"}). Therefore, the bioavailability of β‐RA does not completely explain the tissue‐specific differences in CoQ metabolism since brain and liver showed similar levels of β‐RA.

The effect of β‐RA over CoQ biosynthetic pathway is mediated by a mild stabilization of the Complex Q {#emmm201809466-sec-0009}
-----------------------------------------------------------------------------------------------------

To try to understand the mechanism involved in the reduction in the levels of DMQ~9~ observed after β‐RA treatment, we quantified the levels of main CoQ biosynthetic proteins. The levels of PDSS2 and COQ2, which are not part of Complex Q, did not experience major changes in the brain ([Appendix Fig S9A and B](#emmm201809466-sup-0008){ref-type="supplementary-material"}), kidneys ([Appendix Fig S9C and D](#emmm201809466-sup-0008){ref-type="supplementary-material"}), and heart ([Appendix Fig S9F and G](#emmm201809466-sup-0008){ref-type="supplementary-material"}) of the three experimental groups, and only a decrease in the COQ2 levels was appreciated in the kidneys of *Coq9* ^*R239X*^ mice ([Appendix Fig S9D](#emmm201809466-sup-0008){ref-type="supplementary-material"}). The levels of COQ4, COQ5, COQ6, COQ7, and COQ8A, which are components of the Complex Q, were consistently decreased in the brain (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}A--E), kidneys (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}F--J), and heart (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}K--O) of *Coq9* ^*R239X*^ mice compared to the same tissues in *Coq9* ^+/+^ mice. Interestingly, the treatment with β‐RA induced a trend toward increase on the levels of COQ4, COQ5, COQ6, and COQ8A in the kidneys (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}F, G, H and J) and heart (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}K, L, M and O), but not in the brain (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}A, B, C and E). On the contrary, the levels of COQ7, which physically interacts with COQ9, were not modified by the β‐RA treatment in any of the three tissues (Fig [6](#emmm201809466-fig-0006){ref-type="fig"}D, J and T). Overall, these results suggest that β‐RA may induce the stabilization of the Complex Q, resulting in a decrease in the DMQ~9~/CoQ~9~ ratio.

![Effect of β‐RA treatment in the tissue levels of CoQ biosynthetic proteins\
A--ORepresentative images of Western blots of the CoQ biosynthetic proteins COQ4, COQ5, COQ6, COQ7, and COQ8A and the quantitation of the protein bands in the brain (A--E), kidneys (F--J), and heart (K--O) of *Coq9* ^+/+^, *Coq9* ^*R239X*^, and *Coq9* ^*R239X*^ mice treated with β‐RA. *Coq9* ^+/+^ mice*, Coq9* ^*R239X*^ mice, and *Coq9* ^*R239X*^ mice after β‐RA treatment were included in all graphs. Data are expressed as mean ± SD. \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001; *Coq9* ^*R239X*^ or *Coq9* ^*R239X*^ after β‐RA treatment versus *Coq9* ^+/+^. ^+^ *P* \< 0.05; *Coq9* ^*R239X*^ versus and *Coq9* ^*R239X*^ after β‐RA treatment (one‐way ANOVA with a Tukey\'s *post hoc* test; *n* = 5 for each group; see [Appendix Table S6](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values).\
Source data are available online for this figure.](EMMM-11-e9466-g009){#emmm201809466-fig-0006}

The levels of DMQ~9~ contribute to the disease phenotype {#emmm201809466-sec-0010}
--------------------------------------------------------

The results of the previous sections suggest that the DMQ~9~/CoQ~9~ ratio is a key factor in the disease phenotype. To validate those results, we calculated the DMQ~9~/CoQ~9~ ratio in the tissues of two additional experimental models: (i) the *Coq9* ^*Q95X*^ mouse model, which have widespread CoQ deficiency without compromising the lifespan (Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}); and (ii) the *Coq9* ^*R239X*^ mice treated with ubiquinol‐10, which show an increase in the levels of CoQ~10~ (Garcia‐Corzo *et al*, [2014](#emmm201809466-bib-0024){ref-type="ref"}), resulting in an increase in the lifespan (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}A); yet, this increased lifespan is not comparable to the one observed under β‐RA treatment (Fig [1](#emmm201809466-fig-0001){ref-type="fig"}A). Our results show that, at 1 month of age, the DMQ~9~/CoQ~9~ ratios in the tissues of *Coq9* ^*Q95X*^ mice were significantly lower than in the tissues of *Coq9* ^*R239X*^ mice (Fig [7](#emmm201809466-fig-0007){ref-type="fig"}A and B; [Appendix Fig S10](#emmm201809466-sup-0008){ref-type="supplementary-material"}). At 3 months of age, the DMQ~9~ almost disappeared in the tissues of *Coq9* ^*Q95X*^, but not in *Coq9* ^*R239X*^ mice (Fig [7](#emmm201809466-fig-0007){ref-type="fig"}C and D; [Appendix Fig S10](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In *Coq9* ^*R239X*^ mice, the treatment with ubiquinol‐10 did not affect the levels of DMQ~9~ and, therefore, the DMQ~9~/CoQ~9~ ratios were still high in all tissues, while the CoQ~10~ was increased (Fig [7](#emmm201809466-fig-0007){ref-type="fig"}E and F; [Appendix Fig S11](#emmm201809466-sup-0008){ref-type="supplementary-material"}). Therefore, those results corroborate the correlation between DMQ~9~/CoQ~9~ ratio and the severity of the disease phenotype.

![DMQ ~9~/CoQ~9~ ratio in other experimental conditions\
A--F(A) DMQ~9~/CoQ~9~ ratio in tissues from *Coq9* ^*R239X*^ and *Coq9* ^*Q95X*^ mice at 1 month of age. (C) DMQ~9~/CoQ~9~ ratio in tissues from *Coq9* ^*R239X*^ and *Coq9* ^*Q95X*^ mice at 3 months of age. (E) DMQ~9~/CoQ~9~ ratio in tissues from *Coq9* ^*R239X*^ mice and *Coq9* ^*R239X*^ mice treated with ubiquinol‐10 during 2 months. (B, D, F) Representative chromatographs showing the different quinones in the kidneys. Data in panels (A, C, E) are expressed as mean ± SD. \*\**P* \< 0.01; \*\*\**P* \< 0.001; *Coq9* ^*Q95X*^ versus *Coq9* ^*R239X*^ (*t*‐test; *n* = 5 for each group; see [Appendix Table S7](#emmm201809466-sup-0008){ref-type="supplementary-material"} for exact *P*‐values).](EMMM-11-e9466-g010){#emmm201809466-fig-0007}

Steroid hormones or FGF21 do not mediate the tissues communication under CoQ deficiency {#emmm201809466-sec-0011}
---------------------------------------------------------------------------------------

Because our data suggest that the modification of CoQ metabolism in peripheral tissues induces a reduction in the brain pathology in *Coq9* ^*R239X*^ mice treated with β‐RA, we tried to identify a circulating signal molecule that may provide this tissue communication (e.g., kidney--brain, muscle--brain, heart--brain, or liver--brain). With that purpose, we quantified the steroid hormones, since some steps of their biosynthesis are localized in mitochondria; and FGF21, a recently identified biomarker for mitochondrial myopathies (Suomalainen *et al*, [2011](#emmm201809466-bib-0063){ref-type="ref"}). The results did not show any differences in the levels of corticosterone between the three experimental groups, both in males and females ([Appendix Fig S12A and B](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In male *Coq9* ^*R239X*^ mice, the levels of androstenedione and testosterone were significantly lower than those in male *Coq9* ^+/+^ mice ([Appendix Fig S9C and D](#emmm201809466-sup-0008){ref-type="supplementary-material"}). After β‐RA treatment, the levels of both hormones were still lower than those in control animals ([Appendix Fig S12C and D](#emmm201809466-sup-0008){ref-type="supplementary-material"}).

The levels of FGF21 in the target organ, the brain, were similar in *Coq9* ^+/+^ and *Coq9* ^*R239X*^ mice, while a slight increase was detected in the precursor form in *Coq9* ^*R239X*^ mice treated with β‐RA, compared to *Coq9* ^*R239X*^ mice ([Appendix Fig S12E](#emmm201809466-sup-0008){ref-type="supplementary-material"}). In the liver, the main secretory organ of FGF21, the levels of FGF21 (both the precursor and the mature form) were similar in the three experimental groups ([Appendix Fig S12F](#emmm201809466-sup-0008){ref-type="supplementary-material"}).

Discussion {#emmm201809466-sec-0012}
==========

The treatment of primary or secondary mitochondrial diseases is, in most cases, still limited to a palliative care. In this study, we identify a novel treatment for primary CoQ deficiency. The treatment is based on the administration of β‐RA, which reduces the molecular, histopathologic, and clinical signs of mitochondrial encephalopathy in a mouse model of encephalopathy associated with CoQ deficiency. The remarkable increase of survival after β‐RA treatment was superior to that observed after ubiquinol‐10 treatment, and the therapeutic effect was succeeded even if the treatment started in a symptomatic period. The striking increase in animal survival and the general health improvement after the β‐RA treatment was achieved even though the levels of CoQ and mitochondrial function were not increased in the brain, which is the most relevant tissue for the development of the disease. In peripheral tissues, however, β‐RA induced a decrease in the DMQ~9~/CoQ~9~ ratio, resulting in a bioenergetics improvement that may exert a key influence on the brain pathology. Accordingly, we provide additional data about the DMQ~9~/CoQ~9~ ratio in the *Coq9* ^*Q95X*^ mouse model and in *Coq9* ^*R239X*^ mice treated with ubiquinol‐10, and both cases support the importance of the DMQ~9~/CoQ~9~ ratio in the progression of the clinical symptoms associated with CoQ deficiency syndrome.

The initial hypothesis for this study was that β‐RA could be used in the CoQ biosynthetic pathway and bypasses the defect in COQ9‐COQ7, increasing the endogenous levels of CoQ (Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}; Pierrel, [2017](#emmm201809466-bib-0055){ref-type="ref"}). However, our results show that the bypass effect would be limited because only the kidneys, the tissue with higher levels of β‐RA, showed a moderate increase in the levels of CoQ in the mutant mice after the treatment. Nevertheless, the levels of DMQ~9~ were significantly decreased not only in the kidneys but also in the skeletal muscle, liver, and heart. Those results hint that the CoQ biosynthetic pathway might use β‐RA as a substrate whose Km is probably higher than the natural substrate, 4‐HB, and for that reason the reduction of the DMQ~9~ levels is not accompanied by an increase of CoQ~9~ in tissues where the β‐RA does not reach a threshold (Pierrel, [2017](#emmm201809466-bib-0055){ref-type="ref"}). Also, the stabilization of the Complex Q may contribute to this effect, since the levels of COQ4, COQ5, COQ6, and COQ8A were slightly increased in the kidneys and heart after β‐RA treatment. Consistent with those results, 4‐HB or vanillic acid induced an increase of the CoQ biosynthetic protein *in vitro* (Herebian *et al*, [2017b](#emmm201809466-bib-0029){ref-type="ref"},[c](#emmm201809466-bib-0030){ref-type="ref"}). Moreover, we must also consider that the β‐RA administration was able to increase the levels of CoQ~9~ in renal and cardiac mitochondria, as well as in muscle tissue in a conditional *Coq7* KO model, which lacks COQ7 protein (Wang *et al*, [2015](#emmm201809466-bib-0068){ref-type="ref"}, [2017](#emmm201809466-bib-0070){ref-type="ref"}). Nevertheless, the cerebral CoQ~9~ levels after β‐RA supplementation were not determined in the conditional *Coq7* KO mice (Wang *et al*, [2015](#emmm201809466-bib-0068){ref-type="ref"}, [2017](#emmm201809466-bib-0070){ref-type="ref"}). Because *Coq9* ^*R239X*^ mice has reduced levels not only of COQ7 but also of COQ4, COQ5, COQ6, and COQ8A (Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}), it is also possible that the limitation of the β‐RA to generally increase the CoQ~9~ levels in *Coq9* ^*R239X*^ mice could be due to the disruption of the Complex Q observed in this mouse model. The combination of both arguments could explain the lack of effect over the CoQ biosynthesis pathway in the brain. In either case, our data on the *Coq9* ^*R239X*^ mouse model together with those obtained in the *Coq7* conditional KO model indicate that it is possible to influence the CoQ biosynthesis *in vivo* with the use of the appropriated 4‐HB analog(s). These results partially corroborate previous data *in vitro* using mutant yeasts and human skin fibroblasts derived from patients with primary CoQ deficiency (Ozeir *et al*, [2011](#emmm201809466-bib-0053){ref-type="ref"}; Xie *et al*, [2012](#emmm201809466-bib-0071){ref-type="ref"}; Doimo *et al*, [2014](#emmm201809466-bib-0016){ref-type="ref"}; Freyer *et al*, [2015](#emmm201809466-bib-0022){ref-type="ref"}; Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}; Herebian *et al*, [2017b](#emmm201809466-bib-0029){ref-type="ref"},[c](#emmm201809466-bib-0030){ref-type="ref"}; Pierrel, [2017](#emmm201809466-bib-0055){ref-type="ref"}; Wang *et al*, [2017](#emmm201809466-bib-0070){ref-type="ref"}).

While the levels of CoQ~9~ and CoQ~10~ were doubled in the kidneys of *Coq9* ^*R239X*^ mice after the treatment, the levels reached after the treatment were barely 5% of the wild‐type levels. The reduction in the DMQ~9~ levels after the therapy, and as a consequence, the DMQ~9~/CoQ~9~ ratio, was more important in terms of absolute values, as well as more consistent because the response was similar in all peripheral tissues. Importantly, the decrease in DMQ~9~/CoQ~9~ ratio in peripheral tissues (like kidneys, heart, and muscle) was enough to increase the CoQ‐dependent complexes activities up to normalizing the mitochondrial respiration. Therefore, the effect of the β‐RA treatment in the function of the renal, muscular, and cardiac mitochondria must be due to the reduction of the DMQ~9~/CoQ~9~ ratio. While DMQ is not commercial available to develop more direct experiments, Yang *et al* ([2011](#emmm201809466-bib-0072){ref-type="ref"}) were able to exchange the quinone pools between the mitochondria from wild‐type and Clk‐1 (= Coq7) mutated worms, demonstrating that DMQ~9~ was the responsible of the inhibition of the electron transfer from complex I to ubiquinone in the mitochondrial respiratory chain, probably due to the competition of CoQ and DMQ for the same binding site, together with the inability of DMQ to transfer electrons (Arroyo *et al*, [2006](#emmm201809466-bib-0002){ref-type="ref"}). Our results in mice suggest that DMQ could also inhibit the electron transfer from complex II to ubiquinone, a fact that was not observed in worms (Yang *et al*, [2011](#emmm201809466-bib-0072){ref-type="ref"}). Those differences may reflect the diverse structure and functionality of the mitochondria in different organisms, tissues, and cell types (Vafai & Mootha, [2012](#emmm201809466-bib-0067){ref-type="ref"}). Thus, our study points out the importance of the DMQ~9~/CoQ~9~ ratio in the disease phenotype, a fact that is further supported by several evidences: (i) The *Coq9* ^*Q95X*^ mouse model has low levels of DMQ~9~ and higher levels of CoQ biosynthetic proteins (compared to the *Coq9* ^*R239X*^ muse model), and the lifespan is not compromised; (ii) the treatment with ubiquinol‐10 in *Coq9* ^*R239X*^ mice does not change the DMQ~9~ levels and its therapeutic effects are significantly lower than those after β‐RA treatment; (iii) the reduction in the DMQ~9~ levels in the *Coq7* conditional KO mice after β‐RA therapy may also contribute to the increased survival observed in this mouse model, although the phenotype of this mouse model is not clear (Wang *et al*, [2015](#emmm201809466-bib-0068){ref-type="ref"}); and (iv) patients with high levels of DMQ~10~ in the samples used for the diagnostic (muscle and/or skin fibroblasts) are associated to severe clinical presentations (Duncan *et al*, [2009](#emmm201809466-bib-0017){ref-type="ref"}; Freyer *et al*, [2015](#emmm201809466-bib-0022){ref-type="ref"}; Danhauser *et al*, [2016](#emmm201809466-bib-0009){ref-type="ref"}; Wang *et al*, [2017](#emmm201809466-bib-0070){ref-type="ref"}; Smith *et al*, [2018](#emmm201809466-bib-0062){ref-type="ref"}).

Because the levels of CoQ~9~ and DMQ~9~ did not change in the brain of the *Coq9* ^*R239X*^ mice after the treatment, this tissue did not experience any improvement in the mitochondrial function after β‐RA therapy. However, even if the treatment does not have any detectable effect at the cerebral mitochondria, the *Coq9* ^*R239X*^ mice showed a clear and profound reduction in the spongiform degeneration, reactive astrogliosis, and oxidative damage, leading to an absence of brain injuries after the β‐RA therapy. Those effects are, therefore, independent of the CoQ~9~ and DMQ~9~ levels in the brain. Thus, two complementary hypotheses could explain the therapeutic effects of β‐RA in the brain of *Coq9* ^*R239X*^ mice. First, β‐RA may have CoQ‐independent functions with therapeutic potential for mitochondrial encephalopathies. The transcriptomics data showing a decrease in the expression levels of some inflammatory genes, and the fact that β‐RA is a structural analogue of salicylic acid (Gomez‐Guzman *et al*, [2014](#emmm201809466-bib-0026){ref-type="ref"}), would support this hypothesis. However, our experimental data do not support this hypothesis because: (i) The microglia distribution and the cytokines levels did not experience major changes between *Coq9* ^*R239X*^ mice and *Coq9* ^*R239X*^ mice treated with β‐RA; (ii) β‐RA did not reduce iNOS expression or cytokines release in RAW cells stimulated with LPS; (iii) β‐RA did not have therapeutic effects in pharmacological or genetic models of neuroinflammation, e.g., the MPTP‐induced zebrafish model of Parkinson disease and the *Ndufs4* mouse model of Leigh syndrome; and (iv) β‐RA did not inhibit mTORC1 *in vivo*. Thus, the changes in the expression levels of some inflammatory genes may reflect the reduction in the astrogliosis. In fact, some genes associated with chemokine (e.g., C‐C Motif Chemokine Ligands family) and cytokine signaling (e.g., *Cd14*,*Ifitm3*,*Hmox1*), immune response (*Nurp1*), cell cycle (e.g., *Eif4bpp1*), cell adhesion (e.g., *Ecm1*,*Igfb4*), and lipid metabolism (e.g., *Ch25*) have been also associated to reactive astrogliosis (Zamanian *et al*, [2012](#emmm201809466-bib-0074){ref-type="ref"}; Colombo & Farina, [2016](#emmm201809466-bib-0008){ref-type="ref"}) and, therefore, the reduction observed in these genes could be due to the reduction in the astrogliosis. Our data also suggest that, similarly to other mitochondrial encephalopathies (Lax *et al*, [2012](#emmm201809466-bib-0039){ref-type="ref"}; Tegelberg *et al*, [2017](#emmm201809466-bib-0065){ref-type="ref"}), the neuroinflammation associated with microglia activation is not an important factor in the mitochondrial encephalopathy associated with CoQ deficiency.

The second hypothesis is that the reduction in DMQ~9~/CoQ~9~ ratio in peripheral tissues and the subsequent improvement of mitochondrial bioenergetics may provide some tissue--brain cross‐talk in order to reduce the astrogliosis, spongiosis, and its associated brain injury. While we were not able to reveal how the peripheral tissues communicate with the brain in this situation, a recent study about gene therapy in a mouse model of Leigh syndrome also suggests that the correction of the gene defect in peripheral tissues is important to reduce brain pathology (Di Meo *et al*, [2017](#emmm201809466-bib-0011){ref-type="ref"}). The studies about the kidney--brain, heart--brain, or liver--brain cross‐talk, as well as the presence of a gut--brain axis, would support the concept of an influence of peripheral tissues in the brain pathology, and reactive astrogliosis in particular (Mayo *et al*, [2014](#emmm201809466-bib-0049){ref-type="ref"}; Butterworth, [2015](#emmm201809466-bib-0006){ref-type="ref"}; Rothhammer *et al*, [2016](#emmm201809466-bib-0060){ref-type="ref"}, [2017](#emmm201809466-bib-0061){ref-type="ref"}; Miranda *et al*, [2017](#emmm201809466-bib-0050){ref-type="ref"}; Thackeray *et al*, [2018](#emmm201809466-bib-0066){ref-type="ref"}).

In conclusion, our study shows that β‐RA is a powerful therapeutic agent for the mitochondrial encephalopathy due to CoQ deficiency, a disease that is increasingly diagnosed with exome sequencing, with an estimation of more the 120,000 cases worldwide (Hughes *et al*, [2017](#emmm201809466-bib-0033){ref-type="ref"}). The therapeutic results are greater than those obtained by the classical oral CoQ supplementation because of the decrease of the DMQ/CoQ ratio. Therefore, β‐RA should be preferentially considered for the treatment of human CoQ~10~ deficiency with accumulation of DMQ~10~, as it has been reported in patients with mutations in *COQ9*,*COQ7,* or *COQ4* (Duncan *et al*, [2009](#emmm201809466-bib-0017){ref-type="ref"}; Freyer *et al*, [2015](#emmm201809466-bib-0022){ref-type="ref"}; Danhauser *et al*, [2016](#emmm201809466-bib-0009){ref-type="ref"}; Herebian *et al*, [2017b](#emmm201809466-bib-0029){ref-type="ref"}; Wang *et al*, [2017](#emmm201809466-bib-0070){ref-type="ref"}; Smith *et al*, [2018](#emmm201809466-bib-0062){ref-type="ref"}) but also in cells under siRNA knockdown of *COQ3*,*COQ5* and *COQ6* (Herebian *et al*, [2017b](#emmm201809466-bib-0029){ref-type="ref"}). Similar principles could be applied for 3,4‐hydroxybenzoic acid, vanillic acid, 2‐methyl‐4‐hydroxybenzoic acid, or 2,3‐dimethoxy‐4‐hydroxybenzoic acid in the cases of mutations in *COQ6, COQ5,* or *COQ3* (Heeringa *et al*, [2011](#emmm201809466-bib-0027){ref-type="ref"}; Yoo *et al*, [2012](#emmm201809466-bib-0073){ref-type="ref"}; Ribas *et al*, [2014](#emmm201809466-bib-0058){ref-type="ref"}; Gigante *et al*, [2017](#emmm201809466-bib-0025){ref-type="ref"}; Herebian *et al*, [2017a](#emmm201809466-bib-0028){ref-type="ref"}; Pierrel, [2017](#emmm201809466-bib-0055){ref-type="ref"}), respectively. Furthermore, 4‐HB analogs may provide therapeutic effects in other conditions, e.g., mitochondrial disorders, since secondary CoQ deficiency due to decreased levels of CoQ biosynthetic proteins have been recently reported in various mouse models of mitochondrial diseases (Kuhl *et al*, [2017](#emmm201809466-bib-0037){ref-type="ref"}); or metabolic diseases due to insulin resistance since secondary CoQ deficiency due to decreased levels of CoQ biosynthetic proteins have been recently described in *in vitro* insulin resistance models and adipose tissue from insulin‐resistant humans (Fazakerley *et al*, [2018](#emmm201809466-bib-0020){ref-type="ref"}). To apply the β‐RA treatment into the clinic, the safety and dose--response studies included in a clinical trial should be first developed. Nevertheless, β‐RA is a natural compound that is used as a flavor by the food industry (Adams *et al*, [2005](#emmm201809466-bib-0001){ref-type="ref"}), and its administration in wild‐type mice at high doses does not have detrimental effects on the survival (Wang *et al*, [2015](#emmm201809466-bib-0068){ref-type="ref"}). Therefore, the safety study has a good prognosis and would allow the use of this compound at least as a compassionate option in cases of severe CoQ deficiencies due to mutations in *COQ9* or *COQ7*.

Materials and Methods {#emmm201809466-sec-0013}
=====================

Experimental design {#emmm201809466-sec-0014}
-------------------

*Coq9* ^+/+^ *, Coq9* ^*R239X*^ *, Ndufs4* ^+/+^, and *Ndufs4* ^−/−^ mice were used in the study. All mice have a mix of C57BL/6N and C57BL/6J genetic background. Mice were housed in the Animal Facility of the University of Granada under an SPF zone with lights on at 7:00 AM and off at 7:00 PM. Mice had unlimited access to water and rodent chow. The *Coq9* ^*R239X*^ mouse model (<http://www.informatics.jax.org/allele/key/829271>) was previously generated and characterized (Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}). β‐RA was incorporated in the chow at a concentration of 1%, which provides a dose similar to the one (1 g/kg b.w./day) that was therapeutically successful in the *Coq7* conditional KO model (Wang *et al*, [2015](#emmm201809466-bib-0068){ref-type="ref"}). For a particular experiment, we doubled the dose by adding β‐RA into the drinking water at a concentration of 0.5%, neutralizing the water with sodium bicarbonate. Also, a pilot survival study was done with β‐RA in *Ndufs4* knockout mice, which show microgliosis and neuroinflammation (Quintana *et al*, [2010](#emmm201809466-bib-0056){ref-type="ref"}).

The motor coordination was evaluated by rotarod test at different months of age. Systolic blood pressure (SBP) and heart rate (HR) were measured in conscious, prewarmed, and restrained mice by tail‐cuff plethysmography (Digital Pressure Meter LE 5001, Letica S.A., Barcelona, Spain) as described previously (Gomez‐Guzman *et al*, [2014](#emmm201809466-bib-0026){ref-type="ref"}; Luna‐Sanchez *et al*, [2017](#emmm201809466-bib-0048){ref-type="ref"}).

The therapeutic potential of β‐RA was also assessed in zebrafish embryos treated with the neurotoxin 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP), which is used to induce key features of Parkinson disease, including CI inhibition and neuroinflammation (Diaz‐Casado *et al*, [2018](#emmm201809466-bib-0013){ref-type="ref"}). The embryos were exposed to MPTP from 24 hpf to 72 hpf, and β‐RA was added to the wells from 72 hpf to 120 hpf. After completing the experiment protocol, at 120 hpf, the mortality rate was calculated as the percentage of dead embryos with respect to total embryos. Edema, the most common malformations, as well as tail and yolk abnormalities, were macroscopically quantified (Diaz‐Casado *et al*, [2018](#emmm201809466-bib-0013){ref-type="ref"}). Adult zebrafish (*Danio rerio*) of the AB line were provided by ZFBiolabs S.L (Madrid, Spain) and used as breeding stocks. The fish line was maintained in the University of Granada\'s facility at a water temperature of 28.5 ± 1°C and under a photoperiod of 14:10 h (lights on at 08:00 h) in a recirculation aquaculture system (Aquaneering Incorporated, Barcelona, Spain).

Experiments in mice were performed according to a protocol approved by the Institutional Animal Care and Use Committee of the University of Granada (procedures 9‐CEEA‐OH‐2013) and were in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS \# 123) and the Spanish law (R.D. 53/2013). Experiments in zebrafish were performed according to a protocol approved by the Institutional Animal Care and Use Committee of the University of Granada (procedures CEEA 2010‐275).

Histology and immunohistochemistry {#emmm201809466-sec-0015}
----------------------------------

Multiple brain sections (4 μm thickness) were deparaffinized with xylene and stained with hematoxylin and eosin (H&E). Immunohistochemistry was carried out in the same sections, using the following primary antibodies: anti‐GFAP (Millipore, MAB360, dilution 1:400) and anti‐Iba‐1 (Wako, 019‐19741, dilution 1:500). The detection of carbonyl groups as a marker of protein oxidation was performed using a commercial kit (OxyIHC™ Oxidative Stress Detection Kit; S7450, Millipore; Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}).

Type I and type II skeletal muscle fibers were examined through histochemical detection of cytochrome oxidase (COX) and succinate dehydrogenase (SDH) enzymes activity (Tanji & Bonilla, [2008](#emmm201809466-bib-0064){ref-type="ref"}).

*In vivo* MRI and proton MRS {#emmm201809466-sec-0016}
----------------------------

Magnetic resonance imaging and MRS studies were conducted using a 7 T horizontal bore magnet Bruker Biospec TM 70/20 USR designed for small animal experimentation. Following localizer scans, high‐resolution axial and coronal T2‐weighted datasets were acquired in order to visualize any cerebral or structural atrophy and to investigate for potential focal pathologies (Diaz *et al*, [2012](#emmm201809466-bib-0012){ref-type="ref"}).

Transcriptome analysis by RNA‐Seq {#emmm201809466-sec-0017}
---------------------------------

The RNeasy Lipid Tissue Mini Kit (Qiagen) was used to extract total RNAs from the brainstem of five animals in each experimental group. The RNAs were precipitated and their quality and quantity assessed using an Agilent Bioanalyzer 2100 and an RNA 6000 chip (Agilent Technologies). The cDNA libraries were then constructed using the TruSeq RNA Sample Prep Kit v2 (Illumina, Inc.) and their quality checked using an Agilent Bioanalyzer 2100 and a DNA 1000 chip (Agilent Technologies). The libraries were Paired End sequenced in a HiSeq 4000 system (Illumina, Inc.). We aimed for 4--5 Giga Bases outcome per sample. The quality of the resulting sequencing reads was assessed using FastQC. The GRCm38.p5 fasta and gtf files of the reference mouse genome were downloaded from the Ensembl database and indexed using the bwtsw option of BWA (Linden *et al*, [2012](#emmm201809466-bib-0043){ref-type="ref"}). BWA, combined with *xa2multi.pl* and SAMtools (Li *et al*, [2009](#emmm201809466-bib-0040){ref-type="ref"}), was also used for aligning the sequencing reads against the reference genome, and HTSeq was used for counting the number of reads aligned to each genomic locus (Mishanina *et al*, [2015](#emmm201809466-bib-0051){ref-type="ref"}). The alignments and counting were carried out in our local server following the protocols as described (Brzywczy *et al*, [2002](#emmm201809466-bib-0005){ref-type="ref"}; Di Meo *et al*, [2011](#emmm201809466-bib-0010){ref-type="ref"}).

After elimination of the genomic loci that aligned to \< 5 reads in \< 5 samples and normalization of the read counts by library size, the differential gene expression was detected using the Generalized Linear Model (glmLRT option) statistic in EdgeR (Hine *et al*, [2015](#emmm201809466-bib-0031){ref-type="ref"}). We used a 0.05 *P*‐level threshold after False Discovery Rate correction for type I error. The heatmap figure was made using the heatmap function in R (<https://www.r-project.org/>). Annotation of the differentially expressed genes was obtained from the Mouse Genome Informatics (<http://www.informatics.jax.org/>).

Mitochondrial respiration {#emmm201809466-sec-0018}
-------------------------

To isolate fresh mitochondria, mice were sacrificed and the organs were immediately extracted and placed in ice. The final crude mitochondrial pellet was re‐suspended in MAS 1X medium (Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}). Mitochondrial respiration was measured by using an XFe^24^ Extracellular Flux Analyzer (Seahorse Bioscience; Rogers *et al*, [2011](#emmm201809466-bib-0059){ref-type="ref"}). Respiration by the mitochondria was sequentially measured in a coupled state with the substrates (succinate, malate, glutamate, and pyruvate) present (basal respiration or State 2), followed by State 3o (phosphorylating respiration, in the presence of ADP and substrates); State 4 (non‐phosphorylating or resting respiration) was measured after addition of oligomycin when all ADP was consumed, and then maximal uncoupler‐stimulated respiration (State 3u; Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}). All data were expressed in pmol/min/mg protein.

CoQ‐dependent respiratory chain activities {#emmm201809466-sec-0019}
------------------------------------------

Coenzyme Q‐dependent respiratory chain activities were measured in submitochondrial particles, as previously described (Garcia‐Corzo *et al*, [2014](#emmm201809466-bib-0024){ref-type="ref"}). To test whether β‐RA works as a CoQ substitute en the mitochondrial respiratory chain, we also measure the CI‐III activity after adding 50 μM β‐RA into the reaction mix. The results were expressed in nmol reduced cyt c/min/mg prot.

Evaluation of supercomplexes formation by BNGE {#emmm201809466-sec-0020}
----------------------------------------------

Blue native gel electrophoresis (BNGE) was performed on crude mitochondrial fractions from mice kidneys and brain. Mitochondria were isolated and analyzed by BNGE, as previously described (Fernandez‐Vizarra *et al*, [2002](#emmm201809466-bib-0021){ref-type="ref"}). After electrophoresis, the complexes were electroblotted onto PVDF membranes and sequentially tested with specific antibodies against CI, anti‐NDUFA9 (Abcam, ab14713, dilution 1:5,000), CIII, anti‐ubiquinol‐cytochrome c reductase core protein I (Abcam, ab110252, dilution 1:5,000), and VDAC1 (Abcam, ab14734, dilution 1:5,000).

Sample preparation and Western blot analysis in tissues {#emmm201809466-sec-0021}
-------------------------------------------------------

For Western blot analyses in mouse tissues, samples were homogenized and sonicated in T‐PER^®^ buffer (Thermo Scientific) with protease inhibitor cocktail (Pierce). For Western blot analyses in brain mitochondria, the pellets containing the mitochondrial fraction were re‐suspended in RIPA buffer with protease inhibitor cocktail. Protein band intensity was normalized to VDAC1 (mitochondrial proteins), and the data were expressed in terms of percent relative to wild‐type mice or control cells (Luna‐Sanchez *et al*, [2015](#emmm201809466-bib-0047){ref-type="ref"}, [2017](#emmm201809466-bib-0048){ref-type="ref"}). The following primary antibodies were used: anti‐SQRDL (Proteintech, 17256‐1‐AP, dilution 1:500), anti‐PDSS2 (Proteintech, 13544‐1‐AP, dilution 1:500), anti‐COQ2 (Origene, TA341982, dilution 1:2,500), anti‐COQ4 (Proteintech, 16654‐1‐AP, dilution 1:2,000), anti‐COQ5 (Proteintech, 17453‐1‐AP, dilution 1:1,000), anti‐COQ6 (Proteintech, 12481‐1‐AP, dilution 1:500), anti‐COQ7 (Proteintech, 15083‐1‐AP, dilution 1:1,000), anti‐COQ8A (Proteintech, 15528‐1‐AP, dilution 1:2,500), anti‐S6R (Cell Signaling, 2217, dilution 1:1,000), anti‐S6RP (Cell Signaling, 2211, dilution 1:1,000), anti‐FGF21 (Abcam, ab171941, dilution 1:1,000), anti‐VDAC1 (Abcam, ab14734, dilution 1:5,000), anti‐TOM20 (Proteintech, 11802‐1‐AP, dilution 1:5,000), and anti‐GAPDH (Santacruz, sc‐166574, dilution 1:200).

Quantification of CoQ~9~ and CoQ~10~ levels in mice tissues {#emmm201809466-sec-0022}
-----------------------------------------------------------

CoQ~9~ and CoQ~10~ levels were determined via reversed‐phase HPLC coupled to electrochemical (EC) detection (Lopez *et al*, [2010](#emmm201809466-bib-0046){ref-type="ref"}; Garcia‐Corzo *et al*, [2013](#emmm201809466-bib-0023){ref-type="ref"}). The results were expressed in ng CoQ/mg prot.

Quantification of β‐RA levels and screening of potential derivate molecules in mice tissues {#emmm201809466-sec-0023}
-------------------------------------------------------------------------------------------

The levels of β‐RA were quantified tissue extracts by HPLC‐UV. The screening to detect other hydroxybenzoic acid derivate was performed by UPLC‐MS/MS.

Quantification of pro‐inflammatory mediators in murine RAW 264.7 macrophages and brainstem extracts {#emmm201809466-sec-0024}
---------------------------------------------------------------------------------------------------

Concentrations of interleukin (IL)‐1β, IL‐2, interferon‐γ (IFN‐γ), tumor necrosis factor‐α (TNF‐α), and growth regulated oncogene‐α (GRO‐α) were quantified in duplicates in the supernatant of the cell culture of murine RAW 264.7 macrophages and brainstem tissue using ProcartaPlexTM Multiplex immunoassays (eBioscience), as previously described and according to the manufacturer instructions (Hinz *et al*, [2000](#emmm201809466-bib-0032){ref-type="ref"}; Reichmann *et al*, [2015](#emmm201809466-bib-0057){ref-type="ref"}).

Statistical analysis {#emmm201809466-sec-0025}
--------------------

Number of animals in each group were calculated in order to detect gross \~60% changes in the biomarkers measurements (based upon α = 0.05 and power of β = 0.8). We used the application available in: <http://www.biomath.info/power/index.htm>. Animals were genotyped and randomly assigned in experimental groups in separate cages by the technician of the animal facility. Data are expressed as the mean ± SD of 6--10 experiments per group. A one‐way ANOVA with a Tukey\'s *post hoc* test was used to compare the differences between three experimental groups. Studies with two experimental groups were evaluated using unpaired Student\'s *t*‐test. A *P*‐value of \< 0.05 was considered to be statistically significant. A Mann--Whitney *U*‐test was used for the statistic analysis of the hormones measurements. Survival curve was analyzed by log‐rank (Mantel‐Cox) and the Gehan--Breslow--Wilcoxon tests.

Data and software availability {#emmm201809466-sec-0026}
==============================

RNA‐Seq data were generated as described above. The files have been uploaded in the repository Gene Expression Omnibus. The accession number is [GSE120287](GSE120287). All data can be found at <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE120287>.
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###### The paper explained

Problem {#emmm201809466-sec-0031}
-------

CoQ~10~ deficiency is a mitochondrial syndrome with heterogeneous clinical presentations. Typically, the patients with neurological symptoms or the cases with multisystemic affection respond poorly to the high doses of exogenous CoQ~10~ supplementation due to the limitation of this molecule to cross the blood--brain barrier. Therefore, an alternative therapeutic option is needed for these patients.

Results {#emmm201809466-sec-0032}
-------

In this study, we have used a mouse model of mitochondrial encephalopathy due to CoQ deficiency to test a novel therapy based in the administration of β‐resorcylic acid (β‐RA), an analog of 4‐hydroxybenzoic acid (4‐HB), the precursor of the endogenous CoQ biosynthesis. In peripheral tissues, the β‐RA was able to reduce the levels of demethoxyubiquinone, a CoQ biosynthetic intermediate metabolite that is toxic for the mitochondrial respiratory chain. Consequently, the mitochondrial bioenergetics performance was improved in peripheral tissues during β‐RA treatment, leading to a reduction in the spongiosis and astrogliosis in the brain. As a result, the mutant mice treated with β‐RA reached a maximum lifespan of 25 months of age, with a median survival of 22 months of age. This represents a significant increase in the animal survival if we compare the data to those of the untreated mutant mice, which reached a maximum age of 7 months, with a median survival of 5 months of age; or with the CoQ~10~‐treated (in its reduced form, ubiquinol‐10) mutant mice, which reached a maximum age of 17 months, with a median survival of 13 months of age.

Impact {#emmm201809466-sec-0033}
------

The results support the use of β‐RA at least as a compassionate option in cases of severe CoQ deficiencies due to mutations in *COQ9* or *COQ7*. Therefore, these findings deserve additional in depth research in order to translate the use of β‐RA and/or other 4‐HB analogs into the clinical practice.

For more information {#emmm201809466-sec-0034}
====================

\(i\) Online Mendelian Inheritance in Man (OMIM) COQ9: *S. cerevisiae*, homolog of; COQ9: <http://omim.org/entry/612837#0001>

\(ii\) International mito‐patients: <http://www.mitopatients.org/index.html>

\(iii\) The association of mitochondrial disease patients in Spain: <http://www.aepmi.org/publicoIngles/index.php>

\(iv\) The United Mitochondrial Disease Foundation: <http://www.umdf.org/>
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